Amgen competitorsClear all

PRA Health Sciences's top competitors include Viatris, Allergan, Novo Nordisk, AstraZeneca, Biogen, Avantor, Hospira, AbbVie, Coherus BioSciences, Galenica and Roche.
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background
PRA Health Sciences
PRA Health Sciences
PRA Health Sciences is a contract research organization that provides outsourced clinical development services to the biotechnology and pharmaceutical industries.
Viatris
Viatris
Viatris is a healthcare company.
Allergan
Allergan
Allergan is a healthcare company focused on developing, manufacturing, and commercializing branded pharmaceutical, device, biologic, surgical, and regenerative medicine products.
Novo Nordisk
Novo Nordisk
Novo Nordisk is a healthcare company that designs and manufactures pharmaceutical products.
AstraZeneca
AstraZeneca
AstraZeneca is a global science-led biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines.
Biogen
Biogen
Biogen is a biopharmaceutical company that discovers, develops, and delivers innovative therapies for people living with serious neurological and neurodegenerative diseases.
Avantor
Avantor
Avantor is a company providing materials and consumables, equipment and instrumentation as well as services and specialty procurement.
Hospira
Hospira
Is the worlds leading provider of injectable drugs and infusion technologies.
AbbVie
AbbVie
AbbVie is a pharmaceutical company that discovers, develops, and markets both biopharmaceuticals and small molecule drugs.
Coherus BioSciences
Coherus BioSciences
Coherus BioSciences is a biopharmaceutical company that focuses on the biosimilar and immuno-oncology market.
Galenica
Galenica
Galenica is a healthcare services and products company, that operates three business sectors: retail, products and brands, and services.
Roche
Roche
Roche (also known as F. Hoffmann-La Roch) is a biotech company operating through 2 segments: Pharmaceuticals and Diagnostics.
Founding Date
Founding Date
1976
Founding Date
2020
Founding Date
1948
Founding Date
1923
Founding Date
1999
Founding Date
1978
Founding Date
1904
Founding Date
N/A
Founding Date
2013
Founding Date
2010
Founding Date
1927
Founding Date
1896
Type
Type
Subsidiary
Type
Public
Type
Subsidiary
Type
Public
Type
Public
Type
Public
Type
Public
Type
Subsidiary
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Raleigh, US HQ
Buenos Aires, AR
Haymarket, AU
South Yarra, AU
Minsk, BY
Mechelen, BE
São Paulo, BR
see more
Locations
Canonsburg, US HQ
Carole Park, AU
Millers Point, AU
Sofia, BG
Toronto, CA
Beijing, CN
Beijing, CN
see more
Locations
Dublin, IE HQ
Buenos Aires, AR
Gordon, AU
Wien, AT
Machelen, BE
Guarulhos, BR
Sao Paulo, BR
see more
Locations
Bagsværd, DK HQ
Tirana, AL
Tizi Ouzou, DZ
Buenos Aires, AR
Baulkham Hills, AU
Wien, AT
Baku, AZ
see more
Locations
Cambridge, GB HQ
Alger, DZ
Buenos Aires, AR
Haedo, AR
Macquarie Park, AU
Macquarie Park, AU
North Ryde, AU
see more
Locations
Cambridge, US HQ
Vicente López, AR
Macquarie Park, AU
Wien, AT
Machelen, BE
Mississauga, CA
see more
Locations
Radnor, US HQ
Shanghai, CN
Gurugram, IN
Suwon, KR
Ecatepec Estado De México, MX
Arnhem, NL
Gliwice, PL
see more
Locations
Lake Forest, US HQ
Locations
Lake Bluff, US HQ
Alger, DZ
Buenos Aires, AR
Mascot, AU
Wien, AT
Wavre, BE
Sarajevo, BA
see more
Locations
Redwood City, US HQ
Camarillo, US
Locations
Bern, CH HQ
Locations
Basel, CH HQ
Hydra, DZ
Ricardo Rojas, AR
North Ryde, AU
Sydney, AU
Wien, AT
Wien, AT
see more
Employees
Employees
18,1003% increase
Employees
45,000
Employees
17,4003% increase
Employees
44,3262% increase
Employees
76,1008% increase
Employees
7,4005% decrease
Employees
12,4003% increase
Employees
5,576
Employees
29,1601% decrease
Employees
3102% decrease
Employees
4,166
Employees
97,735
Valuation ($)
Valuation ($)
N/A
Valuation ($)
16.8 b
Valuation ($)
N/A
Valuation ($)
207.3 b
Valuation ($)
153.1 b
Valuation ($)
49 b
Valuation ($)
21.6 b
Valuation ($)
N/A
Valuation ($)
208.7 b
Valuation ($)
960.5 m
Valuation ($)
N/A
Valuation ($)
N/A
Twitter followers
Twitter followers
14.4 k
Twitter followers
1.8 k
Twitter followers
4
Twitter followers
38.5 k
Twitter followers
282.6 k
Twitter followers
40.1 k
Twitter followers
1.5 k
Twitter followers
N/A
Twitter followers
71.3 k
Twitter followers
3.8 k
Twitter followers
N/A
Twitter followers
232.4 k
Number of tweets (last 30 days)
Number of tweets (last 30 days)
40
Number of tweets (last 30 days)
29
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
49
Number of tweets (last 30 days)
41
Number of tweets (last 30 days)
30
Number of tweets (last 30 days)
14
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
29
Number of tweets (last 30 days)
12
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
26
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
2.4
Average likes per tweet (last 30 days)
13.3
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
7
Average likes per tweet (last 30 days)
32.2
Average likes per tweet (last 30 days)
14.7
Average likes per tweet (last 30 days)
3.9
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
8
Average likes per tweet (last 30 days)
1.3
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
8.5
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
63.27%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
96.67%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
96.55%
Percentage of tweets with engagement (last 30 days)
83.33%
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
96.15%
Alexa Website Rank
Alexa Website Rank
297387
Alexa Website Rank
N/A
Alexa Website Rank
278554
Alexa Website Rank
192672
Alexa Website Rank
57766
Alexa Website Rank
289178
Alexa Website Rank
173308
Alexa Website Rank
N/A
Alexa Website Rank
96656
Alexa Website Rank
321407
Alexa Website Rank
138525
Alexa Website Rank
45834
Employee Rating
Employee Rating
4
Employee Rating
3.4
Employee Rating
4
Employee Rating
4.1
Employee Rating
4.2
Employee Rating
4.2
Employee Rating
3.3
Employee Rating
4.1
Employee Rating
3.9
Employee Rating
4.4
Employee Rating
3.6
Employee Rating
N/A

Financial

Revenue (est.)
Revenue (est.)
$3.2b (FY, 2020)
Revenue (est.)
$11.8b (FY, 2020)
Revenue (est.)
$16.1b (FY, 2019)
Revenue (est.)
kr122b (FY, 2019)
Revenue (est.)
$24.4b (FY, 2019)
Revenue (est.)
$13.4b (FY, 2020)
Revenue (est.)
$6.4b (FY, 2020)
Revenue (est.)
N/A
Revenue (est.)
$45.8b (FY, 2020)
Revenue (est.)
$475.8m (FY, 2020)
Revenue (est.)
N/A
Revenue (est.)
CHF63.8b (FY, 2019)
Cost of goods
Cost of goods
$2.3b (FY, 2020)
Cost of goods
$8.1b (FY, 2020)
Cost of goods
$2.5b (FY, 2019)
Cost of goods
kr20.1b (FY, 2019)
Cost of goods
$4.9b (FY, 2019)
Cost of goods
$1.8b (FY, 2020)
Cost of goods
$4.3b (FY, 2020)
Cost of goods
N/A
Cost of goods
$15.4b (FY, 2020)
Cost of goods
$37.7m (FY, 2020)
Cost of goods
N/A
Cost of goods
CHF18.4b (FY, 2019)
Gross profit
Gross profit
$868.6m (FY, 2020)
Gross profit
$3.7b (FY, 2020)
Gross profit
$13.6b (FY, 2019)
Gross profit
kr101.9b (FY, 2019)
Gross profit
$19.5b (FY, 2019)
Gross profit
$11.6b (FY, 2020)
Gross profit
$2.1b (FY, 2020)
Gross profit
N/A
Gross profit
$30.4b (FY, 2020)
Gross profit
$438.1m (FY, 2020)
Gross profit
N/A
Gross profit
CHF45.4b (FY, 2019)
Net income
Net income
$197m (FY, 2020)
Net income
($669.9m) (FY, 2020)
Net income
($5.1b) (FY, 2019)
Net income
kr39b (FY, 2019)
Net income
$1.2b (FY, 2019)
Net income
$4.1b (FY, 2020)
Net income
$116.6m (FY, 2020)
Net income
N/A
Net income
$4.6b (FY, 2020)
Net income
$132.2m (FY, 2020)
Net income
N/A
Net income
CHF14.1b (FY, 2019)

Operating

Countries
Countries
N/A
Countries
N/A
Countries
100 (Q1, 2020)
Countries
N/A
Countries
100 (FY, 2020)
Countries
N/A
Countries
180 (FY, 2020)
Countries
N/A
Countries
175 (FY, 2019)
Countries
N/A
Countries
N/A
Countries
N/A
Manufacturing Facilities
Manufacturing Facilities
N/A
Manufacturing Facilities
15 (Dec, 2020)
Manufacturing Facilities
13 (FY, 2019)
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
29 (FY, 2020)
Manufacturing Facilities
N/A
Manufacturing Facilities
14 (FY, 2019)
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Patients
Patients
N/A
Patients
N/A
Patients
N/A
Patients
N/A
Patients
N/A
Patients
N/A
Patients
N/A
Patients
N/A
Patients
52 m (FY, 2019)
Patients
N/A
Patients
N/A
Patients
63.2 m (FY, 2019)
Patients Included in Clinical Trials
Patients Included in Clinical Trials
N/A
Patients Included in Clinical Trials
N/A
Patients Included in Clinical Trials
N/A
Patients Included in Clinical Trials
N/A
Patients Included in Clinical Trials
33 k (FY, 2017)
Patients Included in Clinical Trials
N/A
Patients Included in Clinical Trials
N/A
Patients Included in Clinical Trials
N/A
Patients Included in Clinical Trials
104 k (FY, 2018)
Patients Included in Clinical Trials
N/A
Patients Included in Clinical Trials
N/A
Patients Included in Clinical Trials
282.5 k (FY, 2019)
Phase I Trials Products (Immunology)
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
2 (Mar, 2020)
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
7 (Dec, 2020)
Phase I Trials Products (Neuroscience)
Phase I Trials Products (Neuroscience)
N/A
Phase I Trials Products (Neuroscience)
N/A
Phase I Trials Products (Neuroscience)
N/A
Phase I Trials Products (Neuroscience)
N/A
Phase I Trials Products (Neuroscience)
N/A
Phase I Trials Products (Neuroscience)
N/A
Phase I Trials Products (Neuroscience)
N/A
Phase I Trials Products (Neuroscience)
N/A
Phase I Trials Products (Neuroscience)
3 (Mar, 2020)
Phase I Trials Products (Neuroscience)
N/A
Phase I Trials Products (Neuroscience)
N/A
Phase I Trials Products (Neuroscience)
5 (Dec, 2020)
Phase I Trials Products (Oncology)
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
18 (Mar, 2020)
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
43 (Dec, 2020)
Phase I Trials Products (Other)
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
1 (Mar, 2020)
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
2 (Dec, 2020)
Phase II Trials Products
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
9 (Q3, 2020)
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
1 (FY, 2020)
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products (Immunology)
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
6 (Mar, 2020)
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
9 (Dec, 2020)
Phase II Trials Products (Neuroscience)
Phase II Trials Products (Neuroscience)
N/A
Phase II Trials Products (Neuroscience)
N/A
Phase II Trials Products (Neuroscience)
N/A
Phase II Trials Products (Neuroscience)
N/A
Phase II Trials Products (Neuroscience)
N/A
Phase II Trials Products (Neuroscience)
N/A
Phase II Trials Products (Neuroscience)
N/A
Phase II Trials Products (Neuroscience)
N/A
Phase II Trials Products (Neuroscience)
2 (Mar, 2020)
Phase II Trials Products (Neuroscience)
N/A
Phase II Trials Products (Neuroscience)
N/A
Phase II Trials Products (Neuroscience)
5 (Dec, 2020)
Phase II Trials Products (Oncology)
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
3 (Mar, 2020)
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
7 (Dec, 2020)
Phase II Trials Products (Other)
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
2 (Mar, 2020)
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
3 (Dec, 2020)
Phase III Trials Products
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
6 (Q3, 2020)
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
1 (FY, 2020)
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products (Immunology)
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
11 (Mar, 2020)
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
7 (Dec, 2020)
Phase III Trials Products (Neuroscience)
Phase III Trials Products (Neuroscience)
N/A
Phase III Trials Products (Neuroscience)
N/A
Phase III Trials Products (Neuroscience)
1 (FY, 2019)
Phase III Trials Products (Neuroscience)
N/A
Phase III Trials Products (Neuroscience)
N/A
Phase III Trials Products (Neuroscience)
N/A
Phase III Trials Products (Neuroscience)
N/A
Phase III Trials Products (Neuroscience)
N/A
Phase III Trials Products (Neuroscience)
1 (Mar, 2020)
Phase III Trials Products (Neuroscience)
N/A
Phase III Trials Products (Neuroscience)
N/A
Phase III Trials Products (Neuroscience)
2 (Dec, 2020)
Phase III Trials Products (Oncology)
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
13 (Mar, 2020)
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
26 (Dec, 2020)
Phase III Trials Products (Other)
Phase III Trials Products (Other)
N/A
Phase III Trials Products (Other)
N/A
Phase III Trials Products (Other)
N/A
Phase III Trials Products (Other)
N/A
Phase III Trials Products (Other)
N/A
Phase III Trials Products (Other)
N/A
Phase III Trials Products (Other)
N/A
Phase III Trials Products (Other)
N/A
Phase III Trials Products (Other)
1 (Mar, 2020)
Phase III Trials Products (Other)
N/A
Phase III Trials Products (Other)
N/A
Phase III Trials Products (Other)
1 (Dec, 2020)
Projects in R&D Pipeline
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
171 (FY, 2020)
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
6 (FY, 2020)
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Research and Development Centers
Research and Development Centers
N/A
Research and Development Centers
N/A
Research and Development Centers
N/A
Research and Development Centers
N/A
Research and Development Centers
N/A
Research and Development Centers
N/A
Research and Development Centers
N/A
Research and Development Centers
N/A
Research and Development Centers
8 (FY, 2019)
Research and Development Centers
N/A
Research and Development Centers
N/A
Research and Development Centers
29 (FY, 2019)
Suppliers
Suppliers
N/A
Suppliers
N/A
Suppliers
N/A
Suppliers
N/A
Suppliers
N/A
Suppliers
N/A
Suppliers
4 k (FY, 2019)
Suppliers
N/A
Suppliers
51 k (FY, 2018)
Suppliers
N/A
Suppliers
N/A
Suppliers
N/A

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
$ 1b
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
$ 174.5m
Total funding raised
N/A
Total funding raised
$ 2.8b
For sources of this data, please see the company profile

View company profiles

Viatris
HQ
Canonsburg, US
Employees
45,000

Viatris is a healthcare company.

View company
Allergan
HQ
Dublin, IE

Allergan is a healthcare company focused on developing, manufacturing, and commercializing branded pharmaceutical, device, biologic, surgical, and regenerative medicine products.

View company
Novo Nordisk
HQ
Bagsværd, DK
Employees
44,326↑ 2% increase

Novo Nordisk is a healthcare company that designs and manufactures pharmaceutical products.

View company
AstraZeneca
HQ
Cambridge, GB
Employees
76,100↑ 8% increase

AstraZeneca is a global science-led biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines.

View company